PEE
MCID: PRC031
MIFTS: 34

Preeclampsia/eclampsia 1 (PEE)

Categories: Blood diseases, Genetic diseases

Aliases & Classifications for Preeclampsia/eclampsia 1

MalaCards integrated aliases for Preeclampsia/eclampsia 1:

Name: Preeclampsia/eclampsia 1 57 13
Preeclampsia/eclampsia, Type 1 40
Toxemia of Pregnancy 57
Pre-Eclampsia 73
Preg1 57
Pee1 57
Pee 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
majority of cases are sporadic
occurs in ~3% pregnancies in western populations
clinical manifestation ranges from mild, transient hypertension to hellp syndrome (hemolysis, elevated liver enzymes, and low platelets)


HPO:

32
preeclampsia/eclampsia 1:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Preeclampsia/eclampsia 1

OMIM : 57 Preeclampsia, which along with chronic hypertension and gestational hypertension comprise the hypertensive disorders of pregnancy, is characterized by new hypertension (blood pressure 140/90 or greater) presenting after 20 weeks' gestation with clinically relevant proteinuria. Preeclampsia is 1 of the top 4 causes of maternal mortality and morbidity worldwide (summary by Payne et al., 2011). Preeclampsia is otherwise known as gestational proteinuric hypertension (Davey and MacGillivray, 1988). A high proportion of patients with preeclampsia have glomerular endotheliosis, the unique histopathologic feature of the condition (Fisher et al., 1981). A distinct form of severe preeclampsia is characterized by hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome) (Brown et al., 2000). (189800)

MalaCards based summary : Preeclampsia/eclampsia 1, also known as preeclampsia/eclampsia, type 1, is related to pre-eclampsia and eclampsia, and has symptoms including edema and hyperemesis gravidarum. An important gene associated with Preeclampsia/eclampsia 1 is NSD1 (Nuclear Receptor Binding SET Domain Protein 1). The drugs Methyldopa and Calcium Carbonate have been mentioned in the context of this disorder. Affiliated tissues include liver, placenta and spleen, and related phenotypes are hypertension and seizures

Related Diseases for Preeclampsia/eclampsia 1

Diseases in the Preeclampsia/eclampsia 5 family:

Preeclampsia/eclampsia 1 Preeclampsia/eclampsia 2
Preeclampsia/eclampsia 3 Preeclampsia/eclampsia 4

Diseases related to Preeclampsia/eclampsia 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 23)
# Related Disease Score Top Affiliating Genes
1 pre-eclampsia 31.5 PEE1 NSD1
2 eclampsia 11.2
3 thrombotic thrombocytopenic purpura 11.1
4 perrault syndrome 1 11.1
5 hepatic encephalopathy 10.2
6 encephalopathy 10.2
7 celiac disease 1 10.0
8 anosmia 10.0
9 cerebral hemorrhage 10.0
10 renal hypertension 10.0
11 anuria 10.0
12 placental abruption 10.0
13 gestational trophoblastic tumor 10.0
14 retinal detachment 9.9
15 hydrops fetalis, nonimmune, and/or atrial septal defect 9.9
16 diabetes mellitus 9.9
17 chronic pyelonephritis 9.9
18 pyelonephritis 9.9
19 severe pre-eclampsia 9.9
20 chorioangioma 9.9
21 exophthalmos 9.9
22 fetal edema 9.9
23 hydrops fetalis 9.9

Graphical network of the top 20 diseases related to Preeclampsia/eclampsia 1:



Diseases related to Preeclampsia/eclampsia 1

Symptoms & Phenotypes for Preeclampsia/eclampsia 1

Symptoms via clinical synopsis from OMIM:

57
Genitourinary Kidneys:
proteinuria

Muscle Soft Tissue:
edema

Cardiovascular Vascular:
maternal hypertension (after 20th week gestation, resolved postpartum)

Abdomen Liver:
elevated liver enzymes

Hematology:
thrombocytopenia (hellp syndrome)

Laboratory Abnormalities:
proteinuria
elevated liver enzymes

Growth Other:
intrauterine growth retardation (in fetus)

Prenatal Manifestations Maternal:
maternal hypertension (after 20th week gestation, resolved postpartum)

Neurologic Central Nervous System:
seizures (eclampsia)


Clinical features from OMIM:

189800

Human phenotypes related to Preeclampsia/eclampsia 1:

32 (show all 10)
# Description HPO Frequency HPO Source Accession
1 hypertension 32 HP:0000822
2 seizures 32 HP:0001250
3 proteinuria 32 HP:0000093
4 edema 32 HP:0000969
5 intrauterine growth retardation 32 HP:0001511
6 thrombocytopenia 32 HP:0001873
7 preeclampsia 32 HP:0100602
8 eclampsia 32 HP:0100601
9 maternal hypertension 32 HP:0008071
10 elevated hepatic transaminase 32 HP:0002910

UMLS symptoms related to Preeclampsia/eclampsia 1:


edema, hyperemesis gravidarum

Drugs & Therapeutics for Preeclampsia/eclampsia 1

Drugs for Preeclampsia/eclampsia 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 426)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyldopa Approved Phase 4,Phase 2,Phase 1,Not Applicable 555-30-6 38853
2
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Not Applicable 471-34-1
3
Remifentanil Approved Phase 4,Phase 2,Phase 1 132875-61-7 60815
4
Amlodipine Approved Phase 4 88150-42-9 2162
5
Metformin Approved Phase 4,Phase 2,Phase 3,Not Applicable 657-24-9 14219 4091
6
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 50-78-2 2244
7
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2180-92-9, 38396-39-3 2474
8
Enoxaparin Approved Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 772
9
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 9005-49-6 772 46507594
10
Dalteparin Approved Phase 4,Phase 2,Phase 3,Early Phase 1 9005-49-6
11
leucovorin Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-05-9 6006 143
12
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 50-56-6 439302 53477758
13
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7440-66-6
14
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 90-82-4 7028
15
Phenylephrine Approved Phase 4,Not Applicable 59-42-7 6041
16
Oxymetazoline Approved, Investigational Phase 4,Not Applicable 1491-59-4 4636
17
Ephedrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 299-42-3 9294
18
Misoprostol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 59122-46-2 5282381
19
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7487-88-9 24083
20
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
21
Furosemide Approved, Vet_approved Phase 4,Phase 2 54-31-9 3440
22
Clonidine Approved Phase 4,Phase 1,Phase 2,Not Applicable 4205-90-7 2803
23
Captopril Approved Phase 4 62571-86-2 44093
24
Ibuprofen Approved Phase 4,Phase 2,Phase 3,Not Applicable 15687-27-1 3672
25
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Not Applicable 103-90-2 1983
26
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
27
Nifedipine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 21829-25-4 4485
28
Labetalol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 36894-69-6 3869
29
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
30 tannic acid Approved Phase 4,Phase 3,Not Applicable
31
Insulin Aspart Approved Phase 4,Phase 3,Not Applicable 116094-23-6 16132418
32
Insulin Lispro Approved Phase 4,Not Applicable 133107-64-9
33
Glyburide Approved Phase 4,Not Applicable 10238-21-8 3488
34
Azithromycin Approved Phase 4,Phase 3 83905-01-5 55185 447043
35
Warfarin Approved Phase 4 81-81-2 6691 54678486
36
Insulin Detemir Approved Phase 4,Phase 3,Not Applicable 169148-63-4 5311023
37
Desogestrel Approved Phase 4 54024-22-5 40973
38
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
39
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 77-92-9 311
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
41
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1,Phase 2,Not Applicable 50-14-6 5280793
42
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1406-16-2
43
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 67-97-0 5280795 6221
44
Serine Approved, Nutraceutical Phase 4,Phase 3,Early Phase 1,Not Applicable 56-45-1 5951
45 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Bone Density Conservation Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
47 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Adrenergic Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
50 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 747)
# Name Status NCT ID Phase Drugs
1 Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape) Unknown status NCT01361425 Phase 4 methildopa;placebo
2 Low Dose Calcium to Prevent Preeclampsia Unknown status NCT02338687 Phase 4
3 Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia Unknown status NCT00117546 Phase 4 alpha methyldopa
4 Remifentanil for General Anesthesia in Preeclamptics Unknown status NCT00567957 Phase 4 Remifentanil;Saline
5 Viagra for the Treatment of IUGR Unknown status NCT00347867 Phase 4 Viagra administration in IUGR/PET pregnancies
6 Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation Unknown status NCT02353806 Phase 4 Amlodipine besylate
7 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4 Metformin
8 Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers Completed NCT01729468 Phase 4 Aspirin;Placebo
9 Treatment Approaches to Preeclampsia Completed NCT01030627 Phase 4
10 Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia Completed NCT02699827 Phase 4 Levobupivacaine hydrochloride;Magnesium sulphate;Saline 0.9%
11 Diuretics for Postpartum High Blood Pressure in Preeclampsia Completed NCT02163655 Phase 4 FUROSEMIDE;Placebo
12 Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia Completed NCT01352234 Phase 4 Acetylsalicylic Acid 160 mg;Acetylsalicylic Acid 80 mg
13 Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia Completed NCT01408979 Phase 4 Magnesium sulfate 12 hours;Magnesium sulfate 24 hours
14 Trial of Early Screening Test for Pre-eclampsia and Growth Restriction Completed NCT03674606 Phase 4 Low dose aspirin
15 A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen Completed NCT02091401 Phase 4 Magnesium Sulfate
16 Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure Completed NCT01761916 Phase 4 CLONIDINE;CAPTOPRIL
17 The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy Completed NCT02891174 Phase 4 Ibuprofen;Acetaminophen
18 Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients Completed NCT01972659 Phase 4 placebo;Magnesium Sulphate;sugammadex
19 Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy Completed NCT01912677 Phase 4 Nifedipine;Labetalol;Methyldopa
20 Enoxaparin in the Prevention of Placental Insufficiency in Pregnant Women Completed NCT03528967 Phase 4 Enoxaparin 40 mg / 0.4 mL Prefilled Syringe;Aspirin 100 mg Oral Tablet, Enteric Coated
21 Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies Completed NCT01608347 Phase 4 LMWH+Folic acid;Folic Acid
22 Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT Completed NCT00790062 Phase 4 Oxytocin
23 Timing of Initiation of LMWH Administration in Pregnant Women With APS Completed NCT02326051 Phase 4 Enoxaparin;Enoxaparin
24 Metformin Versus Insulin in Gestational Diabetes Completed NCT01240785 Phase 4 metformin;insulin
25 Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients Completed NCT02466204 Phase 4 corifollitropin alfa;Follitropin Beta
26 Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo Completed NCT00744965 Phase 4 Glyburide;Placebo
27 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women Completed NCT02377349 Phase 4 Saline placebo
28 Impact of Antichlamydial Treatment on the Rate of Preeclampsia Recruiting NCT03233880 Phase 4 Azithromycin 1gm
29 Efficacy and Safety of 1 g Vs 2 g Per Hour Intravenous Maintenance Dose of MgSO4 in Women With Severe Pre-eclampsia Recruiting NCT03164304 Phase 4 Magnesium Sulfate
30 Phenylephrine Versus Ephedrine in Pre-eclampsia Recruiting NCT02025426 Phase 4 Phenylephrine;Ephedrine
31 Early Vascular Adjustments During Hypertensive Pregnancy Recruiting NCT02531490 Phase 4 Labetalol;Nifedipine;Methyldopa
32 Oral Nifedipine Versus Labetalol in Treatment of Postpartum Hypertension Recruiting NCT03449277 Phase 4 Oral Tablet
33 Response to Anti-hypertensives in Pregnant and Postpartum Patients Recruiting NCT03506724 Phase 4 Nifedipine;Labetalol
34 Is Procardia XL 60 mg Q Daily Equivalent to 30 mg XL Given Twice Daily? Recruiting NCT03595982 Phase 4 Procardia XL 30Mg;Procardia XL 60Mg
35 Chronotherapy With Low-dose Aspirin for Primary Prevention Recruiting NCT00725127 Phase 4 aspirin;aspirin
36 A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy Recruiting NCT02920593 Phase 4 Vitamin D3
37 Chronic Hypertension and Pregnancy (CHAP) Project Recruiting NCT02299414 Phase 4 Anti-hypertensive therapy
38 Use of Warfarin After the First Trimester in Pregnant Women With APS Recruiting NCT02303171 Phase 4 Enoxaparin;Warfarin
39 Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology Recruiting NCT03177122 Phase 4 Myo-inositol
40 Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Recruiting NCT03620890 Phase 4 Neutral Protamine Hagedorn (NPH);Detemir insulin
41 A Comparison of Oral Misoprostol and Vaginal Misoprostol for Cervical Ripening and Induction of Labor Recruiting NCT02777190 Phase 4 Misoprostol
42 Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Active, not recruiting NCT02911701 Phase 4 Acetaminophen;Ibuprofen
43 Contraception in Women With Sickle Cell Disease Active, not recruiting NCT02594462 Phase 4 etonogestrel-releasing implant contraceptive
44 The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia Not yet recruiting NCT03735433 Phase 4 162mg aspirin dose
45 Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial Not yet recruiting NCT03318211 Phase 4 Magnesium Sulfate
46 Metformin for Preeclampsia Prevention in Pregnant Women With Type 1 Diabetes Mellitus Not yet recruiting NCT03570632 Phase 4 Metformin
47 Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients Not yet recruiting NCT03237000 Phase 4 MgSO4
48 A Randomized Trial Comparing Oral Misoprostol Alone With Oral Misoprostol Followed by Oxytocin in Women Induced for Hypertension of Pregnancy Not yet recruiting NCT03749902 Phase 4 Oral misoprostol;Oxytocin
49 Metformin Use to Improve Pregnancy Outcome in Women With Type 1 Diabetes. Not yet recruiting NCT03765359 Phase 4 metforminhydrochloride;Placebo Oral Tablet
50 The Effectiveness and Safety of the Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation Not yet recruiting NCT03809221 Phase 4 Triptorelin acetate

Search NIH Clinical Center for Preeclampsia/eclampsia 1

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Preeclampsia/eclampsia 1

Anatomical Context for Preeclampsia/eclampsia 1

MalaCards organs/tissues related to Preeclampsia/eclampsia 1:

41
Liver, Placenta, Spleen

Publications for Preeclampsia/eclampsia 1

Articles related to Preeclampsia/eclampsia 1:

(show all 24)
# Title Authors Year
1
A study of intravaginal misoprostol for induction of labor in toxemia of pregnancy. ( 11597613 )
2001
2
[Bilateral retinal detachment in toxemia of pregnancy]. ( 10526447 )
1999
3
[Changes in serum lipoprotein (a) levels related to hyperlipidemia during pregnancy--comparing normal pregnancy and toxemia of pregnancy]. ( 8721051 )
1996
4
Retinal pigment epithelium tear following toxemia of pregnancy. ( 7549444 )
1995
5
The relationship between clinical signs and hypercoagulable state in toxemia of pregnancy. ( 1828053 )
1991
6
[Blood coagulation and fibrinolytic studies in patients with toxemia of pregnancy]. ( 2273312 )
1990
7
Changes in placental atrial natriuretic peptide receptors associated with severe toxemia of pregnancy. ( 2543965 )
1989
8
HLA antigens-antibodies system and its association with severe toxemia of pregnancy. ( 3973430 )
1985
9
[Ultrastructural and ultracytochemical characteristics of the terminal villi of the placenta in EPH-toxemia of pregnancy]. ( 3006644 )
1985
10
The role of placental urokinase inhibitor in toxemia of pregnancy. ( 6360225 )
1983
11
Observation of an organism found in patients with gestational trophoblastic disease and in patients with toxemia of pregnancy. ( 6295163 )
1983
12
Observation of an organism found in patients with gestational trophoblastic disease and in patients with toxemia of pregnancy. ( 6312798 )
1983
13
[Acute choriocapillaris occlusion and Elschnig's spots during a toxemia of pregnancy (author's transl)]. ( 7264211 )
1981
14
Case report: ruptured spleen, placental abruption and toxemia of pregnancy. Simultaneous complications of pregnancy. ( 927413 )
1977
15
Alkaline phosphatase activity in dialysed urine samples from patients with normal pregnancy, toxemia of pregnancy and chronic pyelonephritis. ( 5720439 )
1968
16
CHORIOANGIOMA AND TOXEMIA OF PREGNANCY. ( 14258033 )
1965
17
Severe abruptio placentae, toxemia of pregnancy, and renal biopsy. A clinicopathologic study. ( 5847911 )
1965
18
THE PATHOGENIC ROLE OF FIBRIN DEPOSITION IN THE GLOMERULAR LESIONS OF TOXEMIA OF PREGNANCY. ( 14078004 )
1963
19
Massive cerebral hemorrhage complicating toxemia of pregnancy. ( 13564171 )
1958
20
Cerebral hemorrhage as a complication in toxemia of pregnancy. ( 13138962 )
1953
21
Subhyaloid hemorrhage and exophthalmos due to ruptured intraventricular aneurysm; a case occurring in toxemia of pregnancy. ( 14914266 )
1952
22
Non-erythroblastotic hydrops fetalis recurring in association with toxemia of pregnancy. ( 18105516 )
1948
23
Toxemia of pregnancy and experimental hypertension; the production and the measurement of experimental renal hypertension. ( 20993713 )
1946
24
TOXEMIA OF PREGNANCY IN THE RABBIT : I. CLINICAL MANIFESTATIONS AND PATHOLOGY. ( 19870636 )
1937

Variations for Preeclampsia/eclampsia 1

ClinVar genetic disease variations for Preeclampsia/eclampsia 1:

6 (show top 50) (show all 137)
# Gene Variation Type Significance SNP ID Assembly Location
1 LOC108281140; MEGF6 NC_000001.11: g.3494849_3514671dup duplication not provided GRCh38 Chromosome 1, 3494849: 3514671
2 LOC108281140; MEGF6 NC_000001.11: g.3494849_3514671dup duplication not provided GRCh37 Chromosome 1, 3411413: 3431235
3 CD160; PDZK1; RNF115 NC_000001.10: g.145625979_145762959del136981 deletion not provided GRCh37 Chromosome 1, 145625979: 145762959
4 KIF26B NM_018012.4(KIF26B): c.1166+53868_1166+59172del deletion not provided GRCh38 Chromosome 1, 245473613: 245478917
5 KIF26B NM_018012.4(KIF26B): c.1166+53868_1166+59172del deletion not provided GRCh37 Chromosome 1, 245636915: 245642219
6 SOX11 NC_000002.11: g.4677905_5958997dup duplication not provided GRCh37 Chromosome 2, 4677905: 5958997
7 LOC730100 NR_135237.1(LOC730100): n.754-62628_754-62323del deletion not provided GRCh38 Chromosome 2, 51699461: 51699766
8 LOC730100 NR_135237.1(LOC730100): n.754-62628_754-62323del deletion not provided GRCh37 Chromosome 2, 51926599: 51926904
9 REV1 NC_000002.12: g.99439301_99445701dup duplication not provided GRCh38 Chromosome 2, 99439301: 99445701
10 REV1 NC_000002.12: g.99439301_99445701dup duplication not provided GRCh37 Chromosome 2, 100055763: 100062163
11 LRP1B NM_018557.2(LRP1B): c.344-65793_344-61550del deletion not provided GRCh38 Chromosome 2, 141316191: 141320434
12 LRP1B NM_018557.2(LRP1B): c.344-65793_344-61550del deletion not provided GRCh37 Chromosome 2, 142073760: 142078003
13 BAZ2B; LOC643072 NM_001282805.1(MARCH7): c.-247472_-1723dup duplication not provided GRCh38 Chromosome 2, 159465277: 159711026
14 BAZ2B; LOC643072 NM_001282805.1(MARCH7): c.-247472_-1723dup duplication not provided GRCh37 Chromosome 2, 160321788: 160567537
15 ACSL3 NC_000002.12: g.222933783_222958423dup duplication not provided GRCh38 Chromosome 2, 222933783: 222958423
16 ACSL3 NC_000002.12: g.222933783_222958423dup duplication not provided GRCh37 Chromosome 2, 223798501: 223823141
17 TM4SF20 NM_024795.3(TM4SF20): c.-14304_183+492dup duplication not provided GRCh38 Chromosome 2, 227378594: 227393572
18 TM4SF20 NM_024795.3(TM4SF20): c.-14304_183+492dup duplication not provided GRCh37 Chromosome 2, 228243310: 228258288
19 LINC01237; LINC01238; LINC01880; LINC01881; LOC285097 NR_110592.1(LINC01238): n.972-495_131503del deletion not provided GRCh38 Chromosome 2, 241975583: 242106609
20 LINC01237; LINC01238; LINC01880; LINC01881; LOC285097 NR_110592.1(LINC01238): n.972-495_131503del deletion not provided GRCh37 Chromosome 2, 242917734: 243048760
21 ARPP21 NC_000003.12: g.35785215_35861393dup duplication not provided GRCh38 Chromosome 3, 35785215: 35861393
22 ARPP21 NC_000003.12: g.35785215_35861393dup duplication not provided GRCh37 Chromosome 3, 35826707: 35902885
23 CTDSPL NM_001008392.1(CTDSPL): c.80-8666_80-2299del deletion not provided GRCh38 Chromosome 3, 37938391: 37944758
24 CTDSPL NM_001008392.1(CTDSPL): c.80-8666_80-2299del deletion not provided GRCh37 Chromosome 3, 37979882: 37986249
25 SFMBT1 NM_016329.3(SFMBT1): c.-130-31770_-130-30021del deletion not provided GRCh38 Chromosome 3, 52999279: 53001028
26 SFMBT1 NM_016329.3(SFMBT1): c.-130-31770_-130-30021del deletion not provided GRCh37 Chromosome 3, 53033295: 53035044
27 LINC02018 NC_000003.12: g.75379524_75556006del176483 deletion not provided GRCh38 Chromosome 3, 75379524: 75556006
28 LINC02018 NC_000003.12: g.75379524_75556006del176483 deletion not provided GRCh37 Chromosome 3, 75428675: 75605157
29 FRG2C; LINC00960; LINC02018; MIR1324 NR_031714.1(MIR1324): n.-251239_47012del deletion not provided GRCh38 Chromosome 3, 75379524: 75677774
30 FRG2C; LINC00960; LINC02018; MIR1324 NR_031714.1(MIR1324): n.-251239_47012del deletion not provided GRCh37 Chromosome 3, 75428675: 75726925
31 ADGRG7; TFG NC_000003.12: g.100632852_100719048dup duplication not provided GRCh38 Chromosome 3, 100632852: 100719048
32 ADGRG7; TFG NC_000003.12: g.100632852_100719048dup duplication not provided GRCh37 Chromosome 3, 100351696: 100437892
33 LINC01322 NR_125764.1(LINC01322): n.201-50931_201-19041del deletion not provided GRCh38 Chromosome 3, 165323328: 165355218
34 LINC01322 NR_125764.1(LINC01322): n.201-50931_201-19041del deletion not provided GRCh37 Chromosome 3, 165041116: 165073006
35 NLGN1 NM_014932.3(NLGN1): c.-320-82616_-320-21032dup duplication not provided GRCh38 Chromosome 3, 173521663: 173583247
36 NLGN1 NM_014932.3(NLGN1): c.-320-82616_-320-21032dup duplication not provided GRCh37 Chromosome 3, 173239453: 173301037
37 ARHGAP24 NM_001025616.2(ARHGAP24): c.-186452_-21+35669dup duplication not provided GRCh38 Chromosome 4, 85289128: 85511228
38 ARHGAP24 NM_001025616.2(ARHGAP24): c.-186452_-21+35669dup duplication not provided GRCh37 Chromosome 4, 86210281: 86432381
39 ZDHHC11 NC_000005.10: g.788531_840602del52072 deletion not provided GRCh38 Chromosome 5, 788531: 840602
40 ZDHHC11 NC_000005.10: g.788531_840602del52072 deletion not provided GRCh37 Chromosome 5, 788646: 840717
41 ZDHHC11 NC_000005.10: g.788531_821611del33081 deletion not provided GRCh38 Chromosome 5, 788531: 821611
42 ZDHHC11 NC_000005.10: g.788531_821611del33081 deletion not provided GRCh37 Chromosome 5, 788646: 821726
43 LINC02112 NC_000005.10: g.9902291_9924485del22195 deletion not provided GRCh38 Chromosome 5, 9902291: 9924485
44 LINC02112 NC_000005.10: g.9902291_9924485del22195 deletion not provided GRCh37 Chromosome 5, 9902403: 9924597
45 LINC01957; LOC101927078 NC_000005.10: g.114538439_114650526del112088 deletion not provided GRCh38 Chromosome 5, 114538439: 114650526
46 LINC01957; LOC101927078 NC_000005.10: g.114538439_114650526del112088 deletion not provided GRCh37 Chromosome 5, 113874136: 113986223
47 HCG26; HCP5; LINC01149; MICA; MICA-AS1; MICB-DT NR_002812.3(HCG26): n.-83887_14635dup duplication not provided GRCh38 Chromosome 6, 31387342: 31485863
48 HCG26; HCP5; LINC01149; MICA; MICA-AS1; MICB-DT NR_002812.3(HCG26): n.-83887_14635dup duplication not provided GRCh37 Chromosome 6, 31355119: 31453640
49 NHSL1 NC_000006.12: g.138588771_138608297del19527 deletion not provided GRCh38 Chromosome 6, 138588771: 138608297
50 NHSL1 NC_000006.12: g.138588771_138608297del19527 deletion not provided GRCh37 Chromosome 6, 138909908: 138929434

Expression for Preeclampsia/eclampsia 1

Search GEO for disease gene expression data for Preeclampsia/eclampsia 1.

Pathways for Preeclampsia/eclampsia 1

GO Terms for Preeclampsia/eclampsia 1

Sources for Preeclampsia/eclampsia 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....